Lilly's Billion-Dollar Deal With CureVac For 'Next Generation' Immunotherapies
Lilly is targeting mRNA-based next-generation immunotherapies in its collaboration with Germany's CureVac, which could be worth more than $1.7bn for the family-office backed biotech.
You may also be interested in...
Lilly Taps Loxo Execs To Bring Back That Biotech Feeling
Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.
$1.6bn ARMO Buy Gives Lilly Its Most Advanced Immuno-Oncology Asset
Eli Lilly & Co. did not rush into the immuno-oncology game like its big pharma peers, but the acquisition of newly public ARMO gives the company its most advanced IO asset via external innovation – an increased focus for Lilly's portfolio.
Biopharma Quarterly Deal-making Statistics, Q4 2017
Biopharma financing finished off 2017 strong with a total value of $14.5 billion in Q4, led again by FOPOs. CVS' massive $77 billion acquisition of Aetna resulted in an all-time quarterly high in the M&A category, and the largest alliances were dominated by the development of vaccines and antibodies.